bioRxiv Science⌕ Search

Biology subjects

SWALE, C.

Publications and source records attributed to SWALE, C..

2 recordsLinked to original sources

Pentachloropseudilin disrupts multiple steps of the Toxoplasma gondii lytic cycle, consistent with predicted multi-myosin engagement

The pharmacological targeting of apicomplexan myosins has emerged as a validated antiparasitic strategy, with selective inhibitors of MyoA demonstrating activity against parasite motility and invasion. However, apicomplexan parasites express multiple unconventional myosins with essential functions throughout their life cycles that remain unexplored pharmacologically. Here, we investigated pentachloropseudilin (PCIP), a reversible allosteric inhibitor characterized against class-I myosins, although canonical class-I myosins are absent from Apicomplexa. Structural modeling predicted PCIP- potentially compatible allosteric pockets in several parasite myosins, including MyoA, MyoF and MyoJ, suggesting interference with multiple myosin-dependent processes. To specifically resolve PCIP-induced phenotypes across the tachyzoite lytic cycle, we combined complementary high-content and high-resolution approaches, including real-time live-cell imaging, quantitative assays and ultrastructure expansion microscopy. This identified distinct steps at which parasite progression was impaired. PCIP rapidly and reversibly inhibited gliding motility and host-cell invasion in a dose- dependent manner within the submicromolar range. A pronounced effect was observed during intracellular development, where PCIP inhibited proliferation and arrested parasites near the onset of daughter-cell budding. Live imaging and expansion microscopy revealed failure to assemble daughter inner membrane complex scaffolds and subpellicular microtubule arrays, and to replicate apicoplast, consistent with disruption of MyoF-dependent processes. This arrest was not simply cytostatic, as even short PCIP exposure prevented a substantial proportion of intracellular tachyzoites from resuming replication following drug removal. At lower concentrations permitting daughter-cell formation, progeny displayed defective final maturation and frequently lost plasma-membrane integrity within an intact parasitophorous vacuole, preventing egress consistent with interference with MyoJ-dependent processes. Together, these findings reveal multiple points of PCIP-induced failure throughout the T. gondii lytic cycle and associate distinct phenotypes with MyoA-, MyoF- and MyoJ-dependent functions. They establish PCIP as a chemical probe for dissecting apicomplexan myosin-dependent processes and support multi-myosin interference as a promising antiparasitic strategy.

cell biology↗

A drug repurposing screen identifies altiratinib as a selective inhibitor of a key regulatory splicing kinase and a potential therapeutic for toxoplasmosis and malaria

Introductory paragraphThe apicomplexa comprise a large phylum of single-celled, obligate intracellular protozoa that infect humans and animals and cause severe parasitic diseases. Available therapeutics against these devastating diseases are limited by suboptimal efficacy and frequent side effects, as well as the emergence and spread of resistance. Here, we use a drug repurposing strategy and identify altiratinib, a compound originally developed to treat glioblastoma, as a promising drug candidate with broad spectrum activity against apicomplexans. Altiratinib is parasiticidal and blocks the development of intracellular zoites in the nanomolar range and with a high selectivity index. We have identified TgPRP4K of T. gondii as the primary target of altiratinib by genetic target deconvolution, highlighting key residues within the kinase catalytic site that, when mutated, confer resistance to the drug. We have further elucidated the molecular basis of the inhibitory mechanism and species selectivity of altiratinib for TgPRP4K as well as for its P. falciparum counterpart PfCLK3. Our data also point to structural features critical for binding of the other PfCLK3 inhibitor, TCMDC-135051. Consistent with the role of this kinase family in splicing in a broad spectrum of eukaryotes, we have shown that altiratinib causes global disruption of splicing, primarily through intron retention in both T. gondii and P. falciparum. Thus, our data establish parasitic PRP4K/CLK3 as a promising pan-apicomplexan target whose repertoire of inhibitors can be expanded by the addition of altiratinib.

microbiology↗